Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials
<b>Background/Objectives</b>: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-Small-Cell Lung Cancer (NSCLC) accounts for 80–90% of all lung cancers. Antibody-Drug Conjugates (ADCs) represent an expanding targeted therapy option for the treatment of NSCLC. The ai...
Saved in:
| Main Authors: | Matteo Gallina, Anna Carollo, Anna Gallina, Sofia Cutaia, Sergio Rizzo, Alessio Provenzani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/5/608 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancements in antibody-drug conjugates as cancer therapeutics
by: Jung Yin Fong, et al.
Published: (2025-08-01) -
Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01) -
Resistance to antibody–drug conjugates: A review
by: Sijia Li, et al.
Published: (2025-02-01) -
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
by: Yuying Jiang, et al.
Published: (2025-02-01) -
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
by: Ruili Wang, et al.
Published: (2025-04-01)